Human Papillomavirus Infection and Related Anal Lesions in HIV-positive Men Who Have Sex With Men
- Conditions
- Hiv Infection
- Interventions
- Procedure: Standard proctologic examinationProcedure: High resolution anoscopyProcedure: Biopsy(ies) during High Resolution AnoscopyProcedure: High Resolution Anoscopy biannually
- Registration Number
- NCT02287961
- Lead Sponsor
- ANRS, Emerging Infectious Diseases
- Brief Summary
Multicentric epidemiological non-comparative study in France characterising evolution of anal Human papillomavirus (HPV) infection and related lesions and evaluating markers associated with the observed evolution.
Estimated enrolment: 500
Principal Outcomes
* Detection of high-grade cytological and histological anal lesions by high resolution anoscopy
* Spontaneous regression of high-grade anal lesions
* Detection of anal HPV infection
Intervention (procedure):
* Patient medical interview (initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits)
* Standard proctologic examination with digital rectal examination and 2 anal swabs (initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits)
* High resolution anoscopy (initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits)
Only if lesion suggestive of Anal Intraepithelial Neoplasia (AIN) detected during High Resolution Anoscopy (HRA):
- anal biopsy(ies) during HRA
Only if high-grade lesion:
- HRA biannually
- Detailed Description
Intervention (procedure):
* Patient medical interview (initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits)
* Standard proctologic examination with digital rectal examination and 2 anal swabs (initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits)
* High resolution anoscopy (initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits)
Only if lesion suggestive of Anal Intraepithelial Neoplasia (AIN) detected during High Resolution Anoscopy (HRA):
- anal biopsy(ies) during HRA
Only if high-grade lesion (Atypical squamous cells-cannot exclude high-grade squamous intraepithelial lesion (ASC-H), High grade Superficial Intra-epithelial Lesion (HSIL) or AIN2/3):
- HRA biannually
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 516
- Men who have sex with men
- At least 35 years old
- HIV-positive (documented search of HIV infection, with HIV status determined according to HAS algorithm)
- Signed informed consent
- Affiliated to or beneficiary of French social security
- All severity criteria and evolution of HIV disease are accepted (including AIDS stage and co-infections)
- Contraindication to biopsy
- History of anal cancer or pelvic radiotherapy
- AIN2/3 treated during previous year
- Current anticancer chemotherapy or within 24 months before inclusion
- Difficulty in evaluation (anus reshaped and/or scarred)
- Individual placed under judicial protection
- Foreseen absence which may hamper participation; insufficient motivation; associated pathology with priority for care
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Subjects High resolution anoscopy * Standard proctologic examination with digital rectal examination and 2 anal swabs at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits * High resolution anoscopy at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits * Biopsy(ies) during High Resolution Anoscopy only if lesion suggestive of AIN detected during High Resolution Anoscopy * High Resolution Anoscopy biannually only if high-grade lesion (ASC-H, HSIL ou AIN2/3) Subjects Biopsy(ies) during High Resolution Anoscopy * Standard proctologic examination with digital rectal examination and 2 anal swabs at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits * High resolution anoscopy at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits * Biopsy(ies) during High Resolution Anoscopy only if lesion suggestive of AIN detected during High Resolution Anoscopy * High Resolution Anoscopy biannually only if high-grade lesion (ASC-H, HSIL ou AIN2/3) Subjects High Resolution Anoscopy biannually * Standard proctologic examination with digital rectal examination and 2 anal swabs at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits * High resolution anoscopy at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits * Biopsy(ies) during High Resolution Anoscopy only if lesion suggestive of AIN detected during High Resolution Anoscopy * High Resolution Anoscopy biannually only if high-grade lesion (ASC-H, HSIL ou AIN2/3) Subjects Standard proctologic examination * Standard proctologic examination with digital rectal examination and 2 anal swabs at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits * High resolution anoscopy at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits * Biopsy(ies) during High Resolution Anoscopy only if lesion suggestive of AIN detected during High Resolution Anoscopy * High Resolution Anoscopy biannually only if high-grade lesion (ASC-H, HSIL ou AIN2/3)
- Primary Outcome Measures
Name Time Method Evaluation of high-grade anal lesions by high resolution anoscopy Initial inclusion visit Quantification of spontaneous regression of high-grade anal lesions Month 24 Evaluation of anal HPV infection by DNA, RNA and protein detection Initial inclusion visit
- Secondary Outcome Measures
Name Time Method Evaluation of anal HPV infection by DNA, RNA and protein detection Month 24
Trial Locations
- Locations (1)
Diaconesses
🇫🇷Paris, France